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Abstract
Depression and anxiety disorders are two of the most common mental illnesses experienced by people within the
United States, affecting 6.7 percent of the adult population
per year. This article will focus on one specific type of depression, major depressive disorder (MDD), characterized by
two or more weeks of depressed mood and/or decreased
interest in normally enjoyed activities. Depression complicates treatment of other disease state(s), making successful
treatment of depression essential in the management of a
patient's overall health. This review will evaluate the pathophysiology, antidepressant treatment, and new approaches
to treatment, specifically vortioxetine, for MDD.
Introduction
Depression and anxiety disorders are two of the most common mental illnesses experienced by people within the
United States, affecting 6.7 percent of the adult population
per year.1 Although there are several classifications of depression, this article will focus on major depressive disorder
(MDD). Our objective is to review the pathophysiology, treatment and new approaches to treatment of MOD for pharmacists and clinicians.
The major symptoms of MDD, as defined by the Diagnostic
and Statistical Manual of Mental Disorders 4th edition (DSM
IV) guidelines, include two or more weeks of depressed
mood and/or anhedonia, which is a decreased interest in
activities that one normally enjoys. Other symptoms include
mental slowing, poor concentration, insomnia or hypersomnia, significant weight loss or gain, altered eating patterns,
altered levels of activity, feelings of guilt and worthlessness,
decreased energy and libido and suicidal ideation. 2 Depression may occur independently, but frequently follows chronic
disease states such as diabetes, hypertension, and chronic
obstructive pulmonary disease, as well as following a lifechanging diagnosis such as cancer or multiple sclerosis. Depression complicates treatment of other disease state(s),
making successful treatment of depression essential in the
management of a patient's overall health. Antidepressants
play a key role in the treatment of this disorder.
Pathophysiology of Depression
In order to understand the mechanism of antidepressants, it
is necessary to review the complex pathophysiology of depression. Neurotransmitters are the chemicals that the brain
uses to communicate and control various aspects of central
nervous system (CNS) function. The neurotransmitters most
implicated in depression are monoamines, specifically serotonin, norepinephrine, and dopamine.
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Serotonin (5-HT) is one of the major neurotransmitters implicated in depression while also functioning to regulate
sleep, appetite, mood and emotional processing.3 Decreased
levels of serotonin transmission have been observed in patients
with depression and linked to an increased risk of suicide. Low
levels of norepinephrine (NE) can also cause symptoms of depression. Norepinephrine is involved in sensory processing,
mood, and anxiety, as well as sympathetic autonomic functions such as increasing blood pressure and heart rate.
Finally, low levels of dopamine (DA) are implicated in
depression as well. Dopamine is involved in mood, reward,
motivation and concentration. Deficiencies in these neurotransmitters often coincide with one another, making it ideal
to use a medication with multiple mechanisms of action.
Although the actual cause of the neurotransmitter deficiencies remains unknown, bolstering their levels has been
clinically shown to improve the symptoms of depression.
Unfortunately there is a delay in therapeutic onset, leading
researchers to explore the adaptive changes induced by
antidepressants. It has been found that chronic exposure to
antidepressants leads to a change in the sensitivity of the neurotransmitter receptor. Therefore, the homeostatic balance of
neurotransmitter systems is thought to be more important
than the increase and decrease of independent neurotransmitters. Effective antidepressant agents aim to restore efficient regulation to the multiple neurotransmitter systems.4
Monoamine Oxidase Inhibitors
The first antidepressants utilized for MDD were the monoamine oxidase inhibitors (MAO!s). Since their debut in therapy, MAOis have been indicated for patients with atypical
depression, and for those patients who are unresponsive to
other antidepressant therapy.s Some of the most common
MAO!s indicated for depression include isocarboxazid,
phenelzine, and high dose selegiline. These drugs act by inhibiting the monoamine oxidase enzyme responsible for the
breakdown of monoamine neurotransmitters.
There are two types of MAO enzymes (A and 8), both of
which are non-selectively inhibited by MAOls. Blockage of
this enzymatic process results in a decrease in the metabolic
decomposition of neurotransmitters, allowing for an increase
in monoamine concentrations in the brain.s MAOI-8 selective
inhibitors have also been used as monotherapy for symptomatic treatment of Parkinson's disease.6
Monoamine oxidase inhibitors have proven to be fairly welltolerated in most patients and convenient due to their once
to twice daily administration without dose titration. 6 In addi-
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tion, the drugs irreversibly bind the MAO enzyme, causing a
lag time between discontinuation of the drug and return of
normal MAO activity, prolonging therapeutic effects.s
Conversely this lag time could be seen as a disadvantage. It
prevents initiation of any additional therapy with another
serotonin modulating agent for at least two weeks due to a
risk of serotonin syndrome, a term used to describe a constellation of adverse effects such as increased agitation/
anxiety, muscle rigidity, fever, hypertensive crisis, convulsions and even death. There are several other drawbacks to
MAOls in the treatment of MOD. In general, they are contraindicated with other MAOJs or any drugs with similar activity
because of the risk of serotonin syndrome.6 Additional concerns have led to a black box warning for MAOis regarding
"Suicidality and Antidepressant Drugs" indicating an increased risk of suicidal thinking and behavior in children,
adolescents, and young adults who take these drugs.s Lastly,
patients taking MAOis must be aware of certain food restrictions while on these medications. Monoamine oxidase inhibitors have a specific interaction with foods containing high
amounts of tyramine which can lead to hypertensive crisis.
These include high-protein foods that have been exposed to
any "aging, fermentation, pickling, smoking, etc." such as
cheese, meats, fish, dairy, beer, and wine-all of which may
be difficult to avoid for some patients.s Overall, while MAOJs
were the first drug class marketed for antidepressant therapy, newer drug classes have replaced them due to these side
effects and restrictions.
Tricyclic Antidepressants
One of the first alternative drug classes to avoid the challenges presented by MAOis is tricyclic antidepressants
(TCAs). This class of antidepressants is named from the
three-ringed structure of its drug molecules.7 Tricyclic antidepressants were considered first-line therapy for depression until the late 1980s, when selective serotonin reuptake
inhibitors (SSRls) were approved.a Today, TCAs are still used
for depression as well as for the treatment of panic disorder,
attention deficit hyperactivity disorder (ADHD), migraines,
eating disorders, smoking cessation, neuropathic pain and
anxiety. According to the World Federation Societies of Biological Psychiatry treatment guidelines, TCAs are generally
considered to be second-line therapy for depression although they may be considered first-line in some instances,
such as in hospitalized patients with severe depression.9 Frequently prescribed TCAs include amitriptyline, nortriptyline,
desipramine and imipramine.1.10
The mechanism of TCAs is not completely understood, but it
is thought they increase serotonin and norepinephrine levels
by blocking their reuptake. TCAs are non-selective and also
bind to histamine, cholinergic and alpha 1-adrenergic receptors. Their mechanism is different from that of selective serotonin or serotonin/norepinephrine reuptake inhibitors,
which primarily inhibit the reuptake of serotoninJ.10 There
are two structural types of TCAs; secondary and tertiary
amines. The secondary amines, like nortriptyline and desipramine, may play a larger role in blocking the reuptake of
norepinephrine. Tertiary amines such as amitriptyline and
imipramine may be more selective for blocking the reuptake
May 2013 Volume 4, Issue 2

CNS

of serotonin. Even though their structures vary, both secondary and tertiary amines effectively treat depression.10
Tricyclic antidepressants have certain advantages over other
classes of antidepressants. Firstly, they do not interact with
tyramine containing compounds and therefore do not cause
the hypertensive crises for which the MAOJs are known.a
Secondly, TCAs have several indications and may be beneficial for patients who suffer from other conditions that TCAs
treat, such as neuropathic pain, as well as depression.7
Although TCAs may be beneficial for patients who do not
respond to other antidepressants, there are disadvantages in
choosing an antidepressant from this class. Many patients
have difficulty tolerating TCAs due to their many adverse
effects. Tricyclic antidepressants have an increased risk of
overdose and are not as selective as the SSRis. This risk of
overdose is due to cardiac disturbances, which can result
from patients consuming alcohol or taking other medications, such as central nervous system (CNS) depressants and
thyroid agents, with their TCA. Children have an increased
risk of acute overdoses that result in fatality.1.10,12 The many
adverse effects of TCAs result from the class' lack of selectivity. Since TCAs bind non-selectively to a variety of receptors,
they may cause weight gain, dry mouth, constipation, and
drowsiness.7· 13 The weight gain and anticholinergic effects of
secondary amines are less severe than that caused by tertiary amines. 11 Additionally, TCAs may cause orthostatic hypotension. The alpha-1 receptor blocking activity of TCAs is
responsible for the postural drop in blood pressure.12,14
Stimulation of norepinephrine receptors make desipramine
and nortriptyline safer options for patients who are at risk
for orthostatic hypotension.11 Patients who experience orthostatic hypotension have an increased risk of falling and
fainting, especially those in the elderly population who may
already be on antihypertensive medications. Therefore, secondary amines may be preferential in the elderly population.12,14
In addition to their anticholinergic and antihistamine effects,
both classes of TCAs lower the threshold for and may cause
seizures. Patients with seizure disorders who also take a TCA
must be monitored closely. 12 Tricyclic antidepressants
should not be taken with the other antidepressants and
should be used with caution in patients who are at an increased risk for suicide.7 The lack of selectivity of the TCAs
Jed to the development of the SSRis.
Selective Serotonin Reuptake Inhibitors/ SerotoninNorepinephrine Reuptake Inhibitors
Selective serotonin reuptake inhibitors (SSRis) are the current first-line therapy for the treatment of major depressive
disorder. 1s They are also prescribed and used as anxiolytics
with demonstrated efficacy in the treatment of generalized
anxiety, panic, and obsessive compulsive disorder (OCD).16
Some examples of SSRJs include fluoxetine, paroxetine, sertraline, citalopram, escitalopram and fluvoxamine.
SSRI treatment causes stimulation of receptors on cell bodies
in the raphe nucleus and on the serotonergic terminals. With
repeated treatments of SSR!s, there is a gradual down-
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regulation and desensitization of the receptor mechanisms
causing an inhibition of the reuptake of serotonin at the presynaptic neuronal membrane. Additionally, repeated treatments decrease the expression of serotonin transporters
(SERT) in the nerve terminal, resulting in reduced clearance
of serotonin from the synapse. This enhances and prolongs
the serotonergic neurotransmission due to inability of serotonin to be removed and terminated from the cleft.1 6
There are several advantages of choosing an SSRI over other
antidepressant medications. SSRls, in contrast to TCAs, are
well-tolerated and have a more benign cardiovascular profile,
making them preferred as initial agents for treatment of depression in individuals with cardiovascular disease. The recent
American Heart Association science advisory suggests sertraline and citalopram as first-line drugs for patients with both
depression and coronary heart disease.17 SSRis also have few
anticholinergic and adrenolytic effects. Sedation is minimal or
nonexistent, but some patients tend to be fatigued during the
first few weeks of therapy. Drug interactions are relatively
uncommon, except with drugs that also affect serotonergic
neurotransmission, including monoamine oxidase inhibitors
and anti psychotic agents.is More recently citalopram has been
reported to have a dose-related effect on QT interval prolongation and possible development of torsades de pointe. The
manufacturer does not recommend use of citalopram with
other drugs known to prolong the QT interval.IO
Serotonin-norepinephrine reuptake inhibitors (SNR!s) are
similar to SSRis, but have dual serotonin and norepinephrine
action. Inhibition of both SERT and norepinephrine transporters (NET), causes enhanced serotonergic and/or
noradrenergic neurotransmission. Like SSR!s, the initial inhibition of SERT and NET induces activation of autoreceptors,
but decreases serotonergic neurotransmission presynaptically via a negative feedback mechanism until the receptors
are desensitized. Thus, the serotonin concentration can still
interact with the postsynaptic serotonin receptors. Drugs in
this category include venlafaxine, desvenlafaxine and duloxetine.16
There are several disadvantages that patients should be
aware of due to similar toxicities between SSR!s and SNR!s.
These classes are associated with an increased bleeding risk,
especially in the elderly or in those taking other drugs with
the potential of damaging the gastrointestinal mucosa or interfering with clotting.1a Some patients, especially young
adults and children, can show signs of worsening depression
or become increasingly suicidal during the first few months
of taking SSRls/SNRls. They may also cause weight issues
like weight gain or anorexia. Sexual dysfunction, including
decreased libido and erectile dysfunction, occurred in some
patients. Discontinuation symptoms may arise if a drug in
this class is stopped abruptly, so tapering off is beneficial.
Symptoms of withdrawal include nausea, chills, muscle
aches, insomnia, fatigue and anxiety.ls
Bupropion
Mechanistically unrelated to the previously mentioned antidepressants is the drug bupropion (Wellbutrin®). While the
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mechanism of action is not completely understood, the drug
is known to be an aminoketone, and has proven to selectively
inhibit the neuronal reuptake of dopamine, but not serotonin. It also lacks any actions on MAO and it is thought to
achieve its therapeutic effects mainly by dopaminergic and/
or noradrenergic actions. 19, 20 In terms of its indications, the
brand Wellbutrin® and the associated generic products include labels for depression and seasonal affective disorder
(SAD).19. 21 The brand Zyban® has been specifically approved
for smoking cessation.21
Due to its unique mechanism, bupropion could be advantageous for patients who seek a different type of treatment
method than the other existing drug classes. Specifically, bupropion is well-tolerated in patients who experience orthostatic hypotension while using TCAs.19 Another side effect
of the drug that could be advantageous is weight loss, with the
caveat of a black box warning for use in anorexic patients.20 In
addition to this, the CNS-stimulating effects of bupropion are
dose-related, which can be helpful for general drug administration (i.e. predictable outcomes and adjustments). The
drug's few disadvantages are very serious and should still be
considered. These severe side effects are summed up by a
black box warning on bupropion for suicide ideation and increased risk for seizures. Caution is advised when using bupropion with other drugs known to increase the risk of seizures and is contraindicated in patients with a history of seizures. As with other antidepressants, bupropion is not FDA
approved in children due to risk of suicidal thoughts.19,21
Mirtazapine
Another antidepressant with a novel mechanism of action is
mirtazapine. It was developed as an alternative therapy for
patients who could not tolerate TCAs or SSRis.22 Mirtazapine
is structurally different than all other antidepressants on the
market. It has a tetracyclic structure and is part of the
piperazinoazepine class.23,24 Mirtazapine is an alpha-2 antagonist; blocking alpha-2 receptors on presynaptic neurons.
This blockade causes an increase in norepinephrine release,
which is normally deterred by negative feedback from alpha2 agonists. The alpha-2 receptors on serotonergic neurons
are called heteroreceptors. When these receptors are
blocked, there is an increase in serotonin release. Elevated
levels of serotonin and norepinephrine are associated with
antidepressant and anxiolytic activity.23-25 Mirtazapine also
blocks 5-HT2 and 5-HT3 receptors.23,24 Due to its activity on
alpha-2 and certain serotonin receptors, mirtazapine is used
for the treatment of depression.22-26 Mirtazapine may be used
in combination or augmented with other medications when
patients need additional antidepressant therapy.9
In addition to its antidepressant activity, mirtazapine also
has anxiolytic effects; therefore, it may be beneficial in
patients who suffer from both anxiety and depression. Mirtazapine is known to improve the sleeping patterns of depressed patients. It is better tolerated and has a faster onset
of action than the other antidepressants.23,26 Its quick onset
of action may be due to its dual mechanism of action. 24 Since
mirtazapine has significantly increased activity at central
alpha-2 receptors, it has few peripheral side effects. It does
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not act on dopaminergic or muscarinic receptors, which may
also explain its decreased number of side effects.23 Mirtazapine does not have the sexual side effects caused by SSR!s and
has decreased seizure and overdose risks when compared to
TCAs.22. 24 The incidence of erectile dysfunction and decreased libido are higher in SSR!s, since increased levels of
extracellular serotonin decrease norepinephrine levels.
Norepinephrine is necessary for normal sexual function.27

percent of placebo arm) dropped out. In the vortioxetine
groups, patient dropout was three (3 percent of treatment
arm) and seven (7 percent of treatment arm) for the 5 mg
and 10 mg doses, respectively. Over half of the patients who
dropped out were in the venlafaxine group, with vortioxetine
showing low levels of dropouts at each dose. However, by
looking at both doses of vortioxetine as a whole, the dropout
rate was not statistically different.

Certain patients tolerate mirtazapine better than others. Mirtazapine can cause dry mouth, sedation, increased appetite
and weight gain. The weight gain associated with mirtazapine is less pronounced than that caused by TCAs.23-25 In clinical trials, small numbers of patients experienced hypotension
due to mirtazapine's alpha blocking activity, but this side
effect is less common than in patients taking TCAs.23 Like the
other antidepressants, mirtazapine has a black box warning
for an increased risk of suicidal thoughts. It should not be
taken with MAOis or SSRis, due to the risk of drug-drug interactions.8, 25 Patients should not abruptly stop mirtazapine,
since there is a risk for withdrawaJ.25

In analysis of the primary endpoint of this study, both treatments were superior to placebo, with reducing depression
and anxiety at a significantly higher level than placebo. The
authors concluded that vortioxetine displayed efficacy, and
suggested further trials be conducted. Several studies have
found similar results, indicating that vortioxetine is effective
in treating MDD. However, one study that compared vortioxetine to placebo did not show a significant change in baseline for either treatment arm. The authors postulated that
the restrictive nature of their assessment tool, as well as
their more limited population pool, may have contributed to
the lack of benefit seen in this trial compared to the trials
demonstrating efficacy. 30 Upon reanalyzing their data using
another method, they found a significant improvement from
baseline with vortioxetine. These results are questionable,
given that the study was not designed to use the method that
researchers used to reanalyze the data.

Vortioxetine
All of the drug classes mentioned thus far are used currently
in antidepressant therapy today, albeit some more than others based on the advantages and disadvantages of each class.
However, the need for more efficacious therapies with fewer
side effects continues to fuel further drug development. A
new drug that has currently entered the process of FDA approval is LU AA2104, known as vortioxetine. Vortioxetine
works by a novel, multifaceted mechanism of action. In studies, it has demonstrated action as a 5-HTld, 5-HT3 and
5-HT7-receptor antagonist, 5-HTla-receptor agonist, 5-HTlb
-receptor partial agonist, and inhibits the 5-HT reuptake
transporter. All of these effects would increase the antidepressant action of serotonin, and the drug may also increase
levels of norepinephrine, dopamine, acetylcholine and histamine. It is believed that all of these mechanisms are involved
in the clinical effects of the medication.28
Current studies have released tentative results about vortioxetine. They have consistently shown safety, mild adverse
events and tolerability of the drug. Several project a benefit
from baseline compared to placebo, and comparable efficacy
to drugs that were used as active references in the study. One
such study was a double-blind, placebo-controlled study of
vortioxetine in patients with MDD.29 Patients were assigned
to one of four treatment arms: 5 mg vortioxetine, 10 mg vortioxetine, venlafaxine titrated up to 225 mg/day, or placebo.
The patients participated in a six week experimental period,
followed by a two week taper. Both venlafaxine and vortioxetine showed statistically significant superiority (p-value
<0.0001) to placebo when mean change from baseline in the
Montgomery-Asberg Depression Rating Scale (MADRS) total
score was measured at week 6. Side effects in this study were
generally mild across all treatment groups. Out of the 426
patients, a total of 30 patients dropped out of the study due
to adverse effects. Of the 30 patients who dropped out, 16
were in the venlafaxine group, accounting for 14 percent of
that treatment arm. Of the placebo group, four patients (4
May 2013 Volume 4, Issue 2

In short, vortioxetine appears to be safe and tolerable, with
nausea as the most common adverse effect. It has also shown
efficacy in several trials, warranting further investigation. It is
based on the combined data from these studies that the FDA
has decided to accept the submission of the new drug application for vortioxetine in the treatment of MDD.28 Takeda Global
Research and Development Center, Inc and H. Lundbeck A/S
have announced that, should the FDA approve vortioxetine, it
will be marketed under the trade name Brintellix ®·
Prior to vortioxetine, the development of novel mechanisms
to treat depression had stagnated. Vortioxetine would introduce a meaningful contribution to the field, and the current
results indicate that it may be useful in preventing relapse in
patients with MOD. Results also show that it may have a
milder adverse effect profile than the other antidepressant
treatments.
Major depressive disorder is a highly prevalent disease state
in the United States. Pharmacological interventions focus on
the principle of normalizing key neurotransmitters, such as
serotonin, norepinephrine and dopamine. Progress has been
made in the formulation of antidepressants over the last several decades with a goal of maximizing clinical effect while
minimizing adverse effects. Despite these advancements,
limitations to the use of each antidepressant class merit
investigation of additional clinical options. This research appeared to have stagnated until the introduction of vortioxetine and its novel mechanism of action (MOA). Should this
agent gain FDA approval, it would represent an important
developmental step in the continuing efforts to treat and alleviate depression.
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Drug
Class

Examples of
Drugs in Each
Class

MAO!

isocarboxazid
phenelezine
selegiline

TCA

SSRI

SNRI

Secondary
Amines:
desipramine
nortriptyline
Tertiary
Amines:
amitriptyline
imipramine

fluoxetine
paroxetine
sertraline
citalopram
escitalopram
fluvoxamine

venlafaxine
duloxetine
desvenlafaxine

bupropion

mirtazapine

MOA

Place in Therapy

Advantages

Disadvantages

Inhibit the
metabolism of
monoamines
via Monoamine
Oxidase

Atypical
depression
Patients resistant
to other therapies

Daily and twice
daily dosing
No titrations
Well-tolerated

Dietary restrictions of tyramine
containing foods
Risk of hypertensive crisis
Many drug interactions

Block
reuptake of NE
and 5-HT

Depression
Panic Disorder
ADHD
Migraines
Eating disorders
Smoking
cessation
Neuropathic pain
Anxiety

No dietary
restrictions
Multiple
indications

Increased risk of acute overdose
Nonselective
Anticholinergic effects
Antihistamine effects
Orthostatic hypotension
Increased seizure risk

Selective
Limited CV effects
Few anticholinergic and adrenolytic
effects

Sleepiness
Weight gain
Bleeding Risk
Inhibit CYP450s
Worsening of symptoms in the
first few months of therapy
Withdrawal symptoms if stopped
abruptly
Sexual dysfunction

Desensitize
receptors
Blocks SERT
expression

First-line
treatment for
depression
Anxiety
Panic Disorder
OCD

Inhibit both
SERT and NET
Desensitize
receptors

Depression
Anxiety
Panic disorder
OCD

Dual MOA

Weight gain
Bleeding Risk
Worsening of
symptoms in the first few months
of therapy
Withdrawal symptoms if stopped
abruptly

Selectively inhibits the reuptake of DA

For patients who
experience orthostatic hypotension on TCAs
Depression
Nicotine withdrawal
Social anxiety disorder

Does not cause
orthostatic
hypotension

Lowers seizure threshold

Alpha-2
antagonist
Blocks 5-HT2
and S-HT3
receptors

Depression in patients who
cannot tolerate
TCAs or SSRis
Patients who
suffer anxiety and
depression

Improves
sleeping patterns
Faster onset of
action than other
antidepressants
Few peripheral
adverse effects
Lacks sexual side
effects of SSRls

Withdrawal risk
Can cause blood pressure to drop
Weight gain and seizures
(less than TCAs)

Abbreviations: MAOJ-monoamine oxidase inhibitors, TCA-tricyclic antidepressants, SSRI-selective serotonin reuptake inhibitor,
SNRl-serotonin-norepinephrine reuptake inhibitor, OCD-obsessive compulsive disorder, ADHD-attention-deficit and hyperactivity disorder, CV-cardiovascular, SERT-serotonin transporter, NET-norepinephrine transporter. Note: All have an increased risk
of causing suicidal thoughts.
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